DYNLRB1: A Potential Drug Target and Biomarker for Fasting-Induced Nietsin Biosynthesis

Target Name: DYNLRB1

NCBI ID: G83658

DYNLRB1

DYNLRB1: A Potential Drug Target and Biomarker for Fasting-Induced Nietsin Biosynthesis

Introduction

Fasting-induced neurotransmitter release is a critical adaptive response to changes in nutrient availability that have been shown to play a crucial role in various physiological processes, including memory, learning, and mood regulation. One of the well-established mechanisms underlying this process is the neurotransmitter ketones, such as acetyl-CoA, which are produced by the 尾-hydroxy-butyrate coenzyme A (DHA) synthase (DHAAS) and are involved in the production of ketones from the butyryl-CoA carboxylase (DAC) substrates.

The DYNLRB1 gene, located on chromosome 11p36.1, has been identified as a gene that is involved in the synthesis of ketones from DHAAS substrates. In this article, we will focus on the function of DYNLRB1 and its potential as a drug target or biomarker.

Synthesis of Fasting-Induced Ketones

DHAAS is a key enzyme involved in the synthesis of ketones from DHA, which is a crucial precursor for the production of ketones, such as acetyl-CoA, which is involved in the citric acid cycle and is a key player in the production of energy in the form of ATP. DHAAS is a transmembrane protein that consists of four subunits: 伪, 尾, 纬, and 未 subunits.

The 尾 subunit of DHAAS is known as DYNEIN, which is a protein that contains a catalytic active site and is involved in the catalytic mechanism of the enzyme. DYNEIN has been shown to play a crucial role in the production of ketones from DHA by catalyzing the transfer of a carbonyl group from the substrate D-hydroxy-butyric acid to the carbonyl group of the product ketone.

DYNLRB1: A Potential Drug Target

The DYNLRB1 gene has been shown to be involved in the production of ketones from DHAAS substrates. DYNLRB1 encodes a protein that contains a catalytic active site and is involved in the catalytic mechanism of the enzyme.

The DYNLRB1 gene has been shown to be involved in the production of ketones from DHAAS substrates by catalyzing the transfer of a carbonyl group from the substrate D-hydroxy-butyrate to the carbonyl group of the product ketone.

Dynamics of Fasting-Induced Ketone Synthesis

Fasting-induced ketone synthesis is a critical adaptive response to changes in nutrient availability that have been shown to play a crucial role in various physiological processes, including memory, learning, and mood regulation. The dynamics of fasting-induced ketone synthesis are tightly regulated by multiple factors, including the availability of nutrient substrates, the rate of metabolism, and the levels of enzymes involved in the synthesis of ketones.

The DYNLRB1 gene has been shown to be involved in the production of ketones from DHAAS substrates by catalyzing the transfer of a carbonyl group from the substrate D-hydroxy-butyrate to the carbonyl group of the product ketone.

Biomarker Potential

DYNLRB1 has the potential to be used as a biomarker for detecting changes in ketone synthesis in response to changes in nutrient availability. For example, DYNLRB1 gene expression levels can be used as a marker for

Protein Name: Dynein Light Chain Roadblock-type 1

Functions: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function. Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules

The "DYNLRB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYNLRB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets